Does Presbyterian Healthcare Services Cover Eliquis?

What Is Eliquis and Why Does Coverage Matter?

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) that inhibits factor Xa to reduce thrombus formation. The FDA approved it in December 2012 for stroke prevention in non-valvular atrial fibrillation (AF), and subsequent approvals followed for deep vein thrombosis (DVT) treatment, pulmonary embolism (PE) treatment, and surgical VTE prophylaxis. [1][2] Getting coverage right matters because the list price for a 30-day supply can exceed $600 without insurance, placing it out of reach for many patients who need lifelong anticoagulation.

The Clinical Case for Apixaban

The ARISTOTLE trial (N=18,201) showed apixaban reduced stroke or systemic embolism by 21% compared with warfarin in AF patients (hazard ratio 0.79, 95% CI 0.66 to 0.95, P<0.001 for superiority), with a 31% reduction in major bleeding. [3] Those numbers explain why cardiologists and hematologists often prefer apixaban over older agents.

The AMPLIFY trial (N=5,395) demonstrated that apixaban was non-inferior to conventional therapy (enoxaparin followed by warfarin) for acute DVT/PE treatment while causing significantly less major bleeding (relative risk 0.31, 95% CI 0.17 to 0.55). [4]

Why Insurers Tier It Differently

Apixaban remains one of the most prescribed brand-name drugs in the United States, generating significant pharmacy spend. Payers, including Presbyterian, respond by placing it on higher formulary tiers to encourage use of lower-cost alternatives such as warfarin or rivaroxaban. The American College of Cardiology's 2023 AF guideline notes that all four approved DOACs carry a Class I recommendation for most AF patients, meaning formulary restrictions are driven by cost management rather than clinical inferiority of alternatives. [5]

How Presbyterian Healthcare Services Structures Its Formulary

Presbyterian Health Plan, headquartered in Albuquerque, New Mexico, operates commercial HMO/PPO products, Medicaid managed care (Centennial Care), and Medicare Advantage plans across New Mexico. Each product line maintains its own drug formulary, updated annually each January. [6]

Tier System Overview

Most Presbyterian commercial formularies use a five-tier structure:

• Tier 1: Generic preferred drugs (lowest copay, typically $10, $15)
• Tier 2: Generic non-preferred or low-cost brands (typically $25, $40)
• Tier 3: Preferred brand-name drugs (typically $50, $75)
• Tier 4: Non-preferred brand-name drugs (typically $90, $120 or 25 to 40% coinsurance)
• Tier 5: Specialty drugs (coinsurance, often 20 to 33%)

Eliquis is most frequently placed at Tier 3 or Tier 4 depending on plan year and plan type. Patients on high-deductible plans face full list price until the deductible is met, which can mean hundreds of dollars per fill early in the plan year.

Generic Apixaban and Formulary Lag

The FDA approved the first generic apixaban products in May 2023 after the expiration of key patents. [7] Generic inclusion on formularies does not happen automatically. Presbyterian, like most large payers, must negotiate contracts with generic manufacturers before adding them to lower tiers. As of early 2025, some Presbyterian plan types had begun adding generic apixaban to Tier 1 or Tier 2, while others had not yet completed formulary updates. Always verify your specific plan's current formulary at presbyterianplan.org or call the member services number on your insurance card.

Medicare Advantage Formulary Rules

Presbyterian offers Medicare Advantage plans in New Mexico. CMS requires Medicare Part D formularies to include at least two drugs in each drug class, but does not mandate Eliquis specifically. On Presbyterian's Medicare Advantage formulary, apixaban may appear at a different tier than on commercial plans, and cost-sharing is governed by the plan's Part D benefit design. The CMS Medicare Drug Finder tool at medicare.gov allows direct formulary lookups by plan and ZIP code.

Prior Authorization Requirements for Eliquis at Presbyterian

Prior authorization (PA) is the process by which Presbyterian requires prescribers to document medical necessity before the plan will cover a drug. For Eliquis, PA is required on most Presbyterian commercial and Medicare Advantage plans. [8]

What Triggers a PA Request

A PA is typically triggered when a pharmacy submits a claim for apixaban and the plan's adjudication system flags it. The pharmacy will inform the patient and may contact the prescriber's office directly. The prescriber then submits a PA request, usually via phone, fax, or an electronic portal such as CoverMyMeds.

Documentation Typically Required

Presbyterian's PA criteria for apixaban generally include:

• ICD-10 diagnosis code confirming an approved indication (e.g., I48.0, I48.19 for AF; I82 series for DVT; J93 or I26 for PE)
• Documentation that the patient has non-valvular AF (valvular AF patients may require different anticoagulation pathways)
• Prescriber attestation that warfarin is inappropriate or that the patient failed warfarin therapy (inadequate INR control, side effects, drug interactions, patient preference with clinical justification)
• Renal function labs if step therapy or dose adjustment is relevant (apixaban requires dose reduction to 2.5 mg twice daily if two of three criteria are met: age 80+, weight 60 kg or less, serum creatinine 1.5 mg/dL or higher) [9]
• Evidence of prior anticoagulant therapy if step therapy applies

Step Therapy Considerations

Some Presbyterian plan types include a step-therapy edit requiring a trial of warfarin or rivaroxaban before apixaban is approved. The New Mexico Insurance Code and federal regulations allow step therapy but also require plans to grant exceptions when the step-therapy drug is contraindicated, previously tried and failed, or when a prescriber determines it would cause adverse outcomes. [10] Prescribers should document these circumstances explicitly when requesting a PA.

PA Decision Timelines

Under CMS rules and state insurance regulations, standard PA decisions must be made within 3 business days of receipt of all required information. Urgent or expedited PA requests must be decided within 24 hours. If Presbyterian fails to meet these timelines, the request is generally auto-approved or the patient is entitled to an expedited appeal. [11]

Step-by-Step: Getting Eliquis Approved Through Presbyterian

Navigating a PA or denial does not have to be overwhelming. The process below reflects current CMS and state-level consumer protection standards. [12]

Step 1. Confirm Current Formulary Status

Before anything else, log in to presbyterianplan.org or call the pharmacy benefits number on your card. Verify Eliquis's current tier and whether a PA is required for your specific plan. Formularies change annually and mid-year updates do occur.

Step 2. Have Your Prescriber Submit a PA

Ask your cardiologist, internist, or hematologist to submit a PA with complete clinical documentation. Incomplete submissions are the single most common reason for initial denial. Specifically, include the ICD-10 code, a brief clinical summary, and explicit statements about why alternatives are not appropriate.

Step 3. Request an Exception if Step Therapy Applies

If Presbyterian requires a warfarin trial first but warfarin is not appropriate (labile INR history, drug interactions with other medications, patient occupation or lifestyle making bleeding risk unacceptable), your prescriber can request a formulary exception on clinical grounds. The American Heart Association has noted that some patients with AF have documented difficulty maintaining therapeutic INR on warfarin, which is a valid exception basis. [13]

Step 4. Appeal a Denial

If the PA is denied, you have the right to appeal. Presbyterian must provide a written denial with the specific reason. Your prescriber submits a Level 1 internal appeal with additional supporting documentation. If that fails, a Level 2 external appeal goes to an independent review organization (IRO). Studies of Medicare Part D appeals show that roughly 40 to 60% of denials are overturned when additional clinical evidence is provided. [14]

Step 5. Use Patient Assistance While Appealing

Bristol-Myers Squibb and Pfizer, the co-manufacturers of Eliquis, offer a copay assistance program for commercially insured patients. Eligible patients may pay as little as $10 per month while the appeal is pending. The BMS patient assistance line is 1-855-ELIQUIS. Patients without insurance may qualify for the free drug program if their income is below 400% of the federal poverty level.

Covered Alternatives to Eliquis on Presbyterian Formularies

When apixaban is denied or placed at an unaffordable tier, clinicians have several evidence-based alternatives to consider. The choice depends on indication, renal function, and bleeding risk profile. [15]

Warfarin (Coumadin)

Warfarin is Tier 1 on virtually every formulary. It requires regular INR monitoring (target 2.0 to 3.0 for AF and DVT/PE) and has multiple drug and food interactions. The RE-LY, ROCKET-AF, ARISTOTLE, and ENGAGE-AF trials all used warfarin as the active comparator, confirming it reduces AF stroke risk by roughly 64% vs. Placebo. [16] For patients who can maintain a stable INR, warfarin remains a clinically reasonable option.

Rivaroxaban (Xarelto)

Rivaroxaban, another factor Xa inhibitor, is frequently placed at a lower tier than apixaban on Presbyterian formularies because of different manufacturer rebate arrangements. The ROCKET-AF trial (N=14,264) showed rivaroxaban was non-inferior to warfarin for stroke prevention in AF (HR 0.88, 95% CI 0.75 to 1.03 for the per-protocol population). [17] Once-daily dosing may improve adherence for some patients.

Dabigatran (Pradaxa)

Dabigatran, a direct thrombin inhibitor, was studied in RE-LY (N=18,113) and showed the 150 mg twice-daily dose reduced stroke by 34% compared with warfarin, with similar major bleeding rates. [18] Dabigatran requires twice-daily dosing and is contraindicated in severe renal impairment (CrCl <15 mL/min). Its formulary tier at Presbyterian varies by plan year.

Edoxaban (Savaysa)

Edoxaban is less commonly prescribed but was studied in ENGAGE AF-TIMI 48 (N=21,105), where the 60 mg dose was non-inferior to warfarin for stroke prevention with significantly less major bleeding (HR 0.80, P<0.001). [19] Edoxaban requires initial parenteral anticoagulation for DVT/PE treatment, which limits its convenience in that setting.

Eliquis Dosing Reference for Prescribers Submitting PAs

Accurate dosing documentation in a PA request reduces the chance of a technical denial. The FDA-approved dosing for apixaban is as follows: [20]

• Non-valvular AF: 5 mg twice daily; reduce to 2.5 mg twice daily if two of the following three criteria apply: age 80 or older, body weight 60 kg or less, serum creatinine 1.5 mg/dL or higher.
• DVT/PE treatment: 10 mg twice daily for 7 days, then 5 mg twice daily.
• DVT/PE secondary prevention: 2.5 mg twice daily after at least 6 months of treatment.
• VTE prophylaxis after knee replacement: 2.5 mg twice daily for 12 days.
• VTE prophylaxis after hip replacement: 2.5 mg twice daily for 35 days.

Renal dosing for dialysis patients lacks strong prospective trial data. The FDA label notes that apixaban is not recommended in patients with end-stage renal disease on dialysis unless the potential benefit outweighs risk, a detail worth including in PA documentation for that subset of patients. [20]

Cost Management Strategies If Coverage Is Denied or Incomplete

Even with partial coverage, Eliquis can strain a household budget. Several legitimate cost reduction pathways exist. [21]

Bristol-Myers Squibb / Pfizer Copay Card

For commercially insured patients (not Medicare or Medicaid), the manufacturer copay card can reduce out-of-pocket costs to as low as $10 per 30-day supply. This card cannot be used with federal program insurance by law.

Patient Assistance Programs

Patients without insurance or with income below 400% of the federal poverty level may qualify for free Eliquis through BMS's patient assistance program. Applications are submitted at bmspaf.org.

GoodRx and Mark Cuban's Cost Plus Drugs

GoodRx coupons for brand Eliquis can reduce cash prices at some pharmacies, though significant discounts are more common for generic apixaban. Cost Plus Drugs (costplusdrugs.com) lists generic apixaban pricing and has expanded its formulary since 2023.

90-Day Mail-Order Supply

Presbyterian's pharmacy benefit often provides a lower per-unit cost for 90-day mail-order fills vs. 30-day retail fills. Once a PA is approved, switching to mail order can cut monthly cost by 15 to 25%.

What Presbyterian Members Say: A Clinical Framework for Decision-Making

The following four-question framework, developed by the HealthRX medical team based on Presbyterian formulary review and current DOAC guideline criteria, can help prescribers and patients decide the fastest path to approved anticoagulation.

Question 1. Is warfarin clinically acceptable for this patient? If yes, start warfarin while the Eliquis PA is pending. This satisfies step therapy and keeps the patient protected.

Question 2. Is there a documented contraindication or clinical reason to avoid warfarin and rivaroxaban? If yes, document it explicitly in the PA. This is the strongest basis for a step-therapy exception.

Question 3. Has the patient previously failed another DOAC or warfarin? Document dates, INR logs, or adverse event records. Prior failure is the clearest PA approval trigger.

Question 4. Is generic apixaban now listed on this plan's formulary? If yes, prescribe the generic. The prescriber may need to write "apixaban" rather than "Eliquis" for the generic to dispense.

Understanding Your Rights as a Presbyterian Member

Federal and New Mexico state law provide meaningful consumer protections around drug coverage denials. [22]

The ACA's Internal and External Appeal Rights

Under the Affordable Care Act, all non-grandfathered health plans must offer an internal appeal process and access to an independent external review. Presbyterian must notify members of appeal rights in every denial letter. The external IRO decision is binding on the plan. [23]

Medicare Advantage Protections

Medicare Advantage members have additional CMS-mandated protections, including the right to request a redetermination, a reconsideration by a Qualified Independent Contractor, and ultimately an Administrative Law Judge hearing if the disputed drug cost exceeds $180 (2025 threshold). [24]

New Mexico State Insurance Division

The New Mexico Office of Superintendent of Insurance accepts complaints from Presbyterian members who believe their appeals were mishandled. Filing a complaint often prompts faster internal resolution from the insurer.

FAQs